Northwest Biotherapeutics (NWBO) Times Interest Earned (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Times Interest Earned of -$4.65 for Q1 2026, up 57.0% year-over-year from -$2.96 in Q1 2025, and up 9.79% quarter-over-quarter from -$5.15 in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Times Interest Earned (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Times Interest Earned history runs 17 years deep, the most recent figure standing at -$4.65 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 57.0% year-over-year to -$4.65; the TTM figure through Mar 2026 stood at -$5.82 (up 98.01% YoY), while the FY2025 annual figure was -$6.89, down 2813.62% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$4.65, up from -$5.15 in the prior quarter.
- The five-year high for Times Interest Earned was $3.84 in Q4 2023, with the low at -$21.11 in Q4 2022.
- The 5-year median for Times Interest Earned is -$7.12 (2024), against an average of -$7.15.
- Peak annual rise in Times Interest Earned reached 118.18% in 2023, while the deepest fall reached 5868.15% in 2023.
- Northwest Biotherapeutics' Times Interest Earned stood at -$21.11 in 2022, then soared by 118.18% to $3.84 in 2023, then fell by 6.4% to $3.59 in 2024, then sank by 243.35% to -$5.15 in 2025, then climbed by 9.79% to -$4.65 in 2026.
- Business Quant data shows NWBO's Times Interest Earned at -$4.65 in Q1 2026, -$5.15 in Q4 2025, and -$5.46 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -6.42 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.42 |
| Mar 31, 2026 | -4.65 |
| Dec 31, 2025 | -5.10 |
| Sep 30, 2025 | -5.46 |
| Jun 30, 2025 | -8.09 |
| Mar 31, 2025 | -10.81 |
| Dec 31, 2024 | -7.44 |
| Sep 30, 2024 | -7.12 |
| Jun 30, 2024 | -10.39 |
| Mar 31, 2024 | -10.37 |
| Dec 31, 2023 | -12.19 |
| Sep 30, 2023 | -8.28 |
| Jun 30, 2023 | -10.43 |
| Mar 31, 2023 | -12.62 |
| Dec 31, 2022 | -14.89 |
| Sep 30, 2022 | -10.33 |
| Jun 30, 2022 | -14.73 |
| Mar 31, 2022 | -6.46 |
| Dec 31, 2021 | -9.26 |
| Sep 30, 2021 | -6.26 |